CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 9 enrolled
Drug / intervention
Anti-inflammatory supplementdietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04633551
NCT04633551N/ACompleted

Supplements to Improve Vascular Inflammation After an Adverse Pregnancy Outcome

University of South Carolina·interventional·Posted Nov 18, 2020·Updated Sep 21, 2023

In Brief

A clinical study evaluating Anti-inflammatory supplement for Pre-Eclampsia and 3 related conditions. Completed, enrolled 9 participants across 1 site.

Detailed Summary

Women who had an adverse pregnancy outcome (APO), such as preeclampsia, preterm birth, or gestational diabetes, have a higher risk for heart disease. Some of the extra risk for heart disease after APOs is thought to be caused by inflammation. Investigators will randomize women who had an APO in the past 3 years to receive an anti-inflammatory supplement or serve as a time control. Investigators will compare blood pressure, arterial stiffness, blood vessel reactivity, and blood markers of inflammation between women who did and did not receive the supplement. Investigators will determine women's attitudes about taking a dietary supplement and measure whether the participants who receive the supplement take all or most of the doses.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedNov 18, 2020
Enrollment StartOct 1, 2020
Primary CompletionJun 30, 2021
Study CompletionMay 30, 2022
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 5.6 years ago

Interventions

Anti-inflammatory supplementdietary

commercially available combination of curcumin, quercitin, resveratrol, and green tea